Lexeo Therapeutics gains intellectual property rights including current and future clinical data from ongoing Weill Cornell Medicine investigator-initiated trial of gene therapy candidate AAVrh.10hFXN...
Clinical-stage genetic medicine company Lexeo Therapeutics has won fast track designation from the US Food and Drug Administration (FDA) for its gene therapy candidate LX2006, designed to treat Friedreich's ataxia (FA) cardiomyopathy
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006
Lexeo Announces Closing of Oversubscribed $95.0 Million Equity Financing
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic
Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights